BIIB – Biogen Inc.

Float Short %

4.63

Margin Of Safety %

Put/Call OI Ratio

0.67

EPS Next Q Diff

0.31

EPS Last/This Y

3.86

EPS This/Next Y

0.12

Price

174.09

Target Price

182.08

Analyst Recom

2.23

Performance Q

21.48

Relative Volume

0.96

Beta

0.13

Ticker: BIIB

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-13	BIIB	164.93	0.76	0.53	78120
2025-11-14	BIIB	167.68	0.77	0.21	79530
2025-11-17	BIIB	164.76	0.74	0.87	81233
2025-11-18	BIIB	168.83	0.75	0.24	82896
2025-11-19	BIIB	167.92	0.73	0.59	85805
2025-11-20	BIIB	168.27	0.73	0.22	86207
2025-11-21	BIIB	175.34	0.72	0.81	87382
2025-11-24	BIIB	176.85	0.61	0.53	73233
2025-11-25	BIIB	181.93	0.62	0.47	75852
2025-11-26	BIIB	181.91	0.61	1.17	76782
2025-12-01	BIIB	177.83	0.62	1.07	75520
2025-12-02	BIIB	180.32	0.67	0.42	77964
2025-12-03	BIIB	180.7	0.68	0.89	78187
2025-12-04	BIIB	182.05	0.68	0.90	78273
2025-12-05	BIIB	181.32	0.69	0.60	78912
2025-12-08	BIIB	179.93	0.62	0.43	73937
2025-12-09	BIIB	175.79	0.62	0.37	74863
2025-12-10	BIIB	177.48	0.62	1.10	75704
2025-12-11	BIIB	173.64	0.66	1.11	79844
2025-12-12	BIIB	174.08	0.67	0.67	80519
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-13	BIIB	164.85	-48.0	309.1	15.08
2025-11-14	BIIB	167.58	-48.0	301.4	15.08
2025-11-17	BIIB	164.76	-48.0	227.0	15.08
2025-11-18	BIIB	168.81	-48.0	318.4	15.06
2025-11-19	BIIB	167.93	-48.0	251.8	15.06
2025-11-20	BIIB	168.16	-48.0	266.5	15.06
2025-11-21	BIIB	175.33	-48.0	356.8	15.06
2025-11-24	BIIB	176.85	-48.0	283.0	15.06
2025-11-25	BIIB	181.96	-49.2	327.6	15.06
2025-11-26	BIIB	181.93	-49.2	263.1	15.06
2025-12-01	BIIB	177.79	-49.2	211.4	15.06
2025-12-02	BIIB	180.18	-49.2	293.3	15.06
2025-12-03	BIIB	180.75	-49.2	270.5	15.06
2025-12-04	BIIB	181.98	-49.2	278.5	15.06
2025-12-05	BIIB	181.30	-49.2	255.3	15.06
2025-12-08	BIIB	180.44	-49.2	-	15.06
2025-12-09	BIIB	175.84	-49.2	207.2	15.06
2025-12-10	BIIB	175.84	-49.2	284.4	15.06
2025-12-11	BIIB	172.50	-49.2	200.7	15.06
2025-12-12	BIIB	174.09	-49.2	283.8	15.07
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-13	BIIB	-2.29	0.61	3.85
2025-11-14	BIIB	-2.29	0.61	3.85
2025-11-17	BIIB	-2.29	3.35	3.85
2025-11-18	BIIB	-2.29	3.35	3.85
2025-11-19	BIIB	-2.29	3.35	3.85
2025-11-20	BIIB	-2.42	3.35	3.85
2025-11-21	BIIB	-1.03	3.35	3.85
2025-11-24	BIIB	-1.03	2.32	3.85
2025-11-25	BIIB	-1.03	2.32	3.85
2025-11-26	BIIB	-1.03	2.32	4.19
2025-12-01	BIIB	-1.03	1.96	4.19
2025-12-02	BIIB	-1.03	1.96	4.19
2025-12-03	BIIB	-1.03	1.96	4.19
2025-12-04	BIIB	-1.03	1.96	4.19
2025-12-05	BIIB	-1.03	1.96	4.19
2025-12-08	BIIB	-1.03	2.36	4.19
2025-12-09	BIIB	-1.03	2.36	4.19
2025-12-10	BIIB	-1.03	2.36	4.63
2025-12-11	BIIB	-1.03	2.36	4.63
2025-12-12	BIIB	-1.03	2.36	4.63
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

[stock_market_widget type="chart" template="candlestick" assets="BIIB" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

3.17

Avg. EPS Est. Current Quarter

1.75

Avg. EPS Est. Next Quarter

3.48

Insider Transactions

-1.03

Institutional Transactions

2.36

Beta

0.13

Average Sales Estimate Current Quarter

2212

Average Sales Estimate Next Quarter

2257

Fair Value

203.63

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

62.9

Max Drawdown 5-Year %

-72.7

Target Price

182.08

P/E

15.88

Forward P/E

11.45

PEG

P/S

2.64

P/B

1.4

P/Free Cash Flow

11.08

EPS

10.97

Average EPS Est. Cur. Y

15.07

EPS Next Y. (Est.)

15.19

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

16.6

Relative Volume

0.96

Return on Equity vs Sector %

-18.1

Return on Equity vs Industry %

-27.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

283.8

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”BIIB” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BIIB” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BIIB” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BIIB” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BIIB” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BIIB” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BIIB” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

Biogen Inc.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 7605

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

stock quote shares BIIB – Biogen Inc. Stock Price stock today

news today BIIB – Biogen Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch BIIB – Biogen Inc. yahoo finance google finance

stock history BIIB – Biogen Inc. invest stock market

stock prices BIIB premarket after hours

ticker BIIB fair value insiders trading

BIIB – Biogen Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: BIIB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y